Arcutis Biotherapeutics, Inc. (ARQT) Ownership
ARQT ownership summary
as of October 18, 2026- Institutions
- 108.6% of shares outstanding
- Insiders
- 1.77% of shares outstanding
- Shares outstanding
- 125.7M
- Float
- 93.8M shares available to trade
- Short interest
- 18.40% 21.7M shares short
- Days to cover
- 6.49 short interest up 17.5% vs prior month
- Institutions 108.56%
- Insiders 1.77%
ARQT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.89% | 12.4M | $358.4M | +110,000 (+0.9%) | June 30, 2026 |
| 2 | BlackRock Inc | 8.39% | 10.5M | $303.9M | +1.3M (+14.6%) | June 30, 2026 |
| 3 | Frazier Life Sciences Management, L.P. | 7.86% | 9.9M | $284.6M | — | June 30, 2026 |
| 4 | Rubric Capital Management LP | 6.58% | 8.3M | $238.4M | — | June 30, 2026 |
| 5 | Polar Capital Holdings PLC | 5.26% | 6.6M | $190.4M | +940,005 (+16.6%) | June 30, 2026 |
| 6 | State Street Corp | 4.63% | 5.8M | $167.8M | −473,357 (−7.5%) | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 3.97% | 5.0M | $143.8M | +117,220 (+2.4%) | June 30, 2026 |
| 8 | Morgan Stanley - Brokerage Accounts | 3.54% | 4.5M | $128.3M | +232,083 (+5.5%) | June 30, 2026 |
| 9 | Jennison Associates LLC | 3.36% | 4.2M | $121.6M | −761,712 (−15.3%) | June 30, 2026 |
| 10 | D. E. Shaw & Co LP | 3.14% | 3.9M | $113.8M | +1.5M (+58.2%) | June 30, 2026 |
| 11 | UBS Group AG | 2.65% | 3.3M | $96.1M | +3,791 (+0.1%) | June 30, 2026 |
| 12 | Bank of America Corp | 2.38% | 3.0M | $86.1M | +766,142 (+34.5%) | June 30, 2026 |
| 13 | Geode Capital Management, LLC | 2.37% | 3.0M | $86.0M | −62,860 (−2.1%) | June 30, 2026 |
| 14 | Vanguard Portfolio Management, LLC | 1.93% | 2.4M | $70.0M | +474,320 (+24.3%) | June 30, 2026 |
| 15 | Orbimed Advisors LLC | 1.62% | 2.0M | $58.9M | +2.0M (0.0%) | June 30, 2026 |
| 16 | Franklin Templeton Inc | 1.54% | 1.9M | $55.7M | −366,961 (−16.0%) | June 30, 2026 |
| 17 | American Century Companies Inc | 1.53% | 1.9M | $55.5M | +461,803 (+31.6%) | June 30, 2026 |
| 18 | HHG PLC | 1.48% | 1.9M | $53.4M | +24,505 (+1.3%) | March 31, 2026 |
| 19 | The Goldman Sachs Group Inc | 1.33% | 1.7M | $48.1M | +65,354 (+4.1%) | June 30, 2026 |
| 20 | Jupiter Topco LLC | 1.12% | 1.4M | $40.6M | +1.4M (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 14 holders added 9.4M shares and 4 cut 1.7M.
ARQT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | iShares Core S&P Small-Cap ETF | 5.42% | 6.8M | $196.3M | +1,560 (+0.0%) | September 30, 2026 |
| 2 | Polar Capital Biotech S Inc | 4.98% | 6.3M | $180.4M | — | August 31, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 2.84% | 3.6M | $103.0M | −5,638 (−0.2%) | August 31, 2026 |
| 4 | State Street® SPDR® S&P® Biotech ETF | 2.42% | 3.0M | $87.6M | −58,100 (−1.9%) | September 30, 2026 |
| 5 | iShares Russell 2000 ETF | 2.35% | 3.0M | $85.3M | −34,112 (−1.1%) | September 30, 2026 |
| 6 | American Century Small Cap Growth Inv | 1.17% | 1.5M | $42.3M | +351,834 (+31.6%) | June 30, 2026 |
| 7 | MEDICAL BioHealth EUR Acc | 1.01% | 1.3M | $36.6M | +269 (+0.0%) | August 31, 2026 |
| 8 | Fidelity Small Cap Index | 0.99% | 1.3M | $36.0M | +10,981 (+0.9%) | July 31, 2026 |
| 9 | Oberweis Small-Cap Opportunities | 0.96% | 1.2M | $34.9M | — | June 30, 2026 |
| 10 | Candriam Eqs L Biotech C USD Cap | 0.86% | 1.1M | $31.3M | +283,513 (+35.3%) | March 31, 2026 |
| 11 | iShares Russell 2000 Growth ETF | 0.85% | 1.1M | $30.9M | −1,355 (−0.1%) | September 30, 2026 |
| 12 | iShares S&P Small-Cap 600 Growth ETF | 0.84% | 1.1M | $30.6M | — | September 30, 2026 |
| 13 | State Street SPDR Port S&P 600 Sm CpETF | 0.83% | 1.0M | $30.1M | — | September 30, 2026 |
| 14 | Franklin Biotechnology Discv A(acc)USD | 0.69% | 870K | $25.1M | — | August 31, 2026 |
| 15 | Baron Discovery Institutional | 0.69% | 867K | $25.0M | — | September 30, 2026 |
| 16 | Simplify Health Care ETF | 0.69% | 864K | $24.9M | — | September 30, 2026 |
| 17 | iShares Biotechnology ETF | 0.68% | 854K | $24.6M | −6,464 (−0.8%) | September 30, 2026 |
| 18 | PGIM Jennison Small Company A | 0.67% | 846K | $24.4M | — | August 31, 2026 |
| 19 | Worldwide Healthcare Ord | 0.60% | 758K | $21.8M | +570,225 (+303.7%) | June 30, 2026 |
| 20 | apo Medical Opportunities R | 0.54% | 683K | $19.7M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ARQT insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Howard G Welgus | Sell | $23.88 | 10,000 | $238,800 |
| 2026-03-03 | Gilbert Ray Cisneros, Jr. | Buy | $23.60 | — | — |
| 2026-03-02 | Larry Todd Edwards | Sell | $25.18 | 3,687 | $92,839 |
| 2026-03-02 | Latha Vairavan | Sell | $25.18 | 2,853 | $71,839 |
| 2026-03-02 | Masaru Matsuda | Sell | $25.30 | 8,733 | $220,945 |
| 2026-03-02 | Patrick Burnett | Sell | $25.18 | 6,287 | $158,307 |
| 2026-03-02 | Todd Watanabe | Sell | $25.18 | 37,349 | $940,448 |
| 2026-02-27 | Masaru Matsuda | Sell | $27.95 | 3,325 | $92,934 |
| 2026-02-04 | Patrick Burnett | Sell | $25.81 | 9,794 | $252,783 |
| 2026-02-02 | Larry Todd Edwards | Sell | $25.50 | 2,052 | $52,326 |
| 2026-02-02 | Todd Watanabe | Sell | $25.50 | 19,833 | $505,742 |
| 2026-02-02 | Patrick Burnett | Sell | $25.50 | 3,675 | $93,712 |
| 2026-02-02 | Masaru Matsuda | Sell | $25.28 | 40,638 | $1.0M |
| 2026-02-02 | Latha Vairavan | Sell | $25.50 | 1,320 | $33,660 |
| 2026-02-02 | Howard G Welgus | Sell | $25.05 | 10,000 | $250,500 |
| 2026-01-05 | Patrick Burnett | Sell | $28.98 | 2,490 | $72,160 |
| 2026-01-02 | Howard G Welgus | Sell | $28.96 | 10,000 | $289,600 |
| 2025-12-31 | Patrick Burnett | Sell | $29.20 | 1,697 | $49,552 |
| 2025-12-15 | Patrick Burnett | Sell | $28.94 | 11,500 | $332,810 |
| 2025-12-11 | Gilbert Ray Cisneros, Jr. | Sell | $29.47 | — | — |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ARQT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ARQT
Institutional investors own 108.6% of Arcutis Biotherapeutics's shares and insiders 1.77%. The largest holder is Suvretta Capital Management, LLC with 9.89% of the shares (12.4M), as of June 30, 2026. Among the top 20 institutions, 14 added shares and 4 reduced their stake in the latest filings. Short interest is 18.40% of the float, or 6.49 days of average trading volume. The share count rose 13,463.5% since 2017.
Related: ARQT analyst forecast, ARQT key metrics. See the ARQT stock overview for the latest quote and news.
ARQT ownership FAQ
Who owns the most Arcutis Biotherapeutics stock?
The largest shareholders of Arcutis Biotherapeutics are Suvretta Capital Management, LLC (9.89%), BlackRock Inc (8.39%), Frazier Life Sciences Management, L.P. (7.86%), Rubric Capital Management LP (6.58%), Polar Capital Holdings PLC (5.26%).
What percentage of Arcutis Biotherapeutics is owned by institutions?
Institutions hold 108.6% of Arcutis Biotherapeutics's shares outstanding; insiders hold 1.77%.
Which funds own Arcutis Biotherapeutics?
The largest fund holders of Arcutis Biotherapeutics are iShares Core S&P Small-Cap ETF (5.42%), Polar Capital Biotech S Inc (4.98%), Vanguard MStar Total Stk Mkt Idx Invest (2.84%), State Street® SPDR® S&P® Biotech ETF (2.42%), iShares Russell 2000 ETF (2.35%).
What is Arcutis Biotherapeutics's short interest?
21.7M shares of Arcutis Biotherapeutics were sold short, 18.40% of the float; at the average daily volume it would take 6.49 days to cover.
Are insiders buying or selling Arcutis Biotherapeutics?
Of the latest 20 reported insider transactions in Arcutis Biotherapeutics (since December 11, 2025), 1 were purchases and 19 were sales.
How many shares of Arcutis Biotherapeutics are outstanding?
Arcutis Biotherapeutics has 125.7M shares outstanding, of which 93.8M are in the public float.